NL-OMON43587
Recruiting
Not Applicable
A phase 1 Study to Evaluate the Safety and Feasibility of Intraoperative Detection of Clear Cell Renal Cell Carcinoma Using Indium-111-DOTA-girentuximab-IRDye800CW - Intraoperative dual-modality imaging in renal cell carcinoma
niversitair Medisch Centrum Sint Radboud0 sites22 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- clear cell renal cell carcinoma
- Sponsor
- niversitair Medisch Centrum Sint Radboud
- Enrollment
- 22
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Clinical diagnosis of primary clear cell renal cell carcinoma or a recurrent or metastatic clear cell renal cell carcinoma lesion planned for surgery;\- Age over 18 years;\- Signed informed consent
Exclusion Criteria
- •\- A known subtype other than clear cell RCC;\- Administration of a radioisotope within 10 physical half lives prior to study enrollment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A phase I/II Study to Evaluate the Safety and Feasibility of Dual-modality imaging using Indium-111-DOTA-labetuzumab-IRDye800CW in patients with Peritoneal Carcinomatosis of Colorectal OrigiNL-OMON45898Radboud Universitair Medisch Centrum29
Active, not recruiting
Phase 1
aEUCTR2019-004883-23-FRAPHP
Active, not recruiting
Phase 1
HTLPSCID pediatric patients (n=12 for analysis) requiring an HLA partially compatible allogeneic HSCT.MedDRA version: 20.0Level: PTClassification code 10010099Term: Combined immunodeficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2018-001029-14-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)12
Completed
Not Applicable
A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Neoplastic Lesions in Patients with Cancer of the Colorectum or PancreasNL-OMON47359Surgimab85
Recruiting
Not Applicable
Study on the detection of cancer during surgery for rectal cancer or pancreatic cancer with the fluorescent agent SGM-101 'rectal cancerpancreatic cancerNL-OMON21037eiden University Medical Center (LUMC) and Centre for Human Drug Research (CHDR), Leiden, the Netherlands30